| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/25/2002 | WO2002030874A3 Aliphatic, cyclic amino carboxylic acids as integrin antagonists |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2002006306A3 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY |
| 07/25/2002 | WO2002002147A3 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 07/25/2002 | WO2002000183A3 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 07/25/2002 | WO2001094413A3 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 07/25/2002 | WO2001090091A8 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/25/2002 | WO2001087307A3 Compositions and methods for the treatment of cancer |
| 07/25/2002 | WO2001078701A3 Method and compositions for preventing hormone induced adverse effects |
| 07/25/2002 | WO2001070798A3 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 07/25/2002 | WO2001070222A3 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 07/25/2002 | WO2001066531A8 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 07/25/2002 | WO2001062289B1 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 07/25/2002 | WO2001060992A3 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 07/25/2002 | WO2001057208A3 Mlp gene, nucleic acids, polypeptides and the utilization thereof |
| 07/25/2002 | WO2001040188A9 Curcumin analogues for treating cancer |
| 07/25/2002 | WO2001039795A9 Attenuation of fibroblast proliferation |
| 07/25/2002 | WO2001034201A9 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 07/25/2002 | WO2001032204A3 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 07/25/2002 | WO2001032186A3 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 07/25/2002 | WO2001030812A9 Activation of hcv-specific t cells |
| 07/25/2002 | WO2001015676A3 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 07/25/2002 | WO2001003716A9 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 07/25/2002 | WO2001002559A9 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 07/25/2002 | WO2001000812A9 22012, a novel human carboxypeptidase |
| 07/25/2002 | WO2001000811A9 17867, a novel human aminopeptidase |
| 07/25/2002 | WO2001000665A9 Inhibitors of memapsin 2 and use thereof |
| 07/25/2002 | WO2000059486A8 Use of cyp2d6 inhibitors in combination therapies |
| 07/25/2002 | US20020100069 Treating heart defects; obtain tissue, incubate with modulator of transcription, evaluate tissue for defect |
| 07/25/2002 | US20020099330 No-releasing compounds are a stabilized s-nitrosyl group and free thiol group coated on medical device, such as a stent or catheter |
| 07/25/2002 | US20020099322 Adhering therapeutic tool |
| 07/25/2002 | US20020099215 For therapy and prophylaxis of P-glycoprotein-mediated multidrug resistance |
| 07/25/2002 | US20020099209 Dihydrostilbene alkanoic acid derivatives |
| 07/25/2002 | US20020099191 EDG8 receptor, its preparation and use |
| 07/25/2002 | US20020099178 Growth-associated protease inhibitor heavy chain precursor |
| 07/25/2002 | US20020099095 For treatment and prophylactic treatment of ageing of the skin, for pretreatment or after-treatment of hair or scalp or of the hair root region, in particular before or after hair treatment, for example during colouring |
| 07/25/2002 | US20020099094 Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris |
| 07/25/2002 | US20020099089 Administering compounds such as trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide or like for therapy of conditions associated with increased telomerase activity, e.g. tumour diseases |
| 07/25/2002 | US20020099079 Treating psoriasis, ulcers, gastroesophageal reflux and conditions caused by gastric hypersecretion including Zollinger-Ellison Syndrome, by administering hydroxylansoprazole or salt |
| 07/25/2002 | US20020099071 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia |
| 07/25/2002 | US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis |
| 07/25/2002 | US20020099061 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease |
| 07/25/2002 | US20020099057 Treatment of accidental extravasation of anthracyclines |
| 07/25/2002 | US20020099045 Administering a sigma receptor ligand in combination with an antidepressant agent; especially for refractory depression |
| 07/25/2002 | US20020099033 Method and composition for treating sleep apnea |
| 07/25/2002 | US20020099031 Hemostatic agent |
| 07/25/2002 | US20020099029 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| 07/25/2002 | US20020099020 Oil blend of omega-3- and omega-6- fatty acids; branched amino acid; antioxidant comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof; in a liquid nutritional matrix. |
| 07/25/2002 | US20020099014 Method for treatment of insulin resistance in obesity and diabetes |
| 07/25/2002 | US20020099012 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020098998 P27 prevents cellular migration |
| 07/25/2002 | US20020098583 Composition for use in the treatment of cell cycle defects, autoimmune diseases, aging, cancer, leukemia and psoriasis |
| 07/25/2002 | US20020098582 Differentiated stem cells suitable for human therapy |
| 07/25/2002 | US20020098580 MDM interacting protein and methods of use thereof |
| 07/25/2002 | US20020098540 Novel polypeptides, and nucleic acids encoding the same |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098199 Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| 07/25/2002 | US20020098190 Delaying development of HMFG- and CEA- associated tumor by administering first antibody comprising light and heavy chain variable region sequences in SEQ ID NO:2 and NO:4, and second antibody comprising sequences in SEQ ID NO:6 and NO:8 |
| 07/25/2002 | US20020098178 Short term treatment with composition having gastrin/cholecystokinin receptor ligand and EGF receptor ligand, resulting in prolonged period of increased insulin release |
| 07/25/2002 | US20020098177 17867, a novel human aminopeptidase |
| 07/25/2002 | DE10103271A1 Pharmaceutical formulation containing hyaluronatlyase, useful for softening of connective tissue in medical and cosmetic treatment, especially in shape correction |
| 07/25/2002 | DE10102944A1 Production of 3-cyano-1H-indol-7-yl)-(4-(4-fluorophenethyl)piperazin-1-yl)-methanone useful as a selective 5-HT2A antagonist comprises use of an indolecarboxylic acid ester as the starting material |
| 07/25/2002 | CA2443080A1 Lipid-based nitric oxide donors |
| 07/25/2002 | CA2437038A1 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 07/25/2002 | CA2435117A1 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434736A1 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | CA2434696A1 P27 prevents cellular migration |
| 07/25/2002 | CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | CA2434490A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | CA2434483A1 Processes for enhanced production of pantothenate |
| 07/25/2002 | CA2434338A1 Pharmaceutical composition having reduced tendency for drug crystallization |
| 07/25/2002 | CA2434270A1 Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | CA2433835A1 Tetrahydropyran derivatives as neurokinin receptor antagonists |
| 07/25/2002 | CA2432800A1 Regulated activation of cell-membrane receptors by metal-chelating agonists |
| 07/25/2002 | CA2432041A1 Polynucleotides encoding human phosphatases |
| 07/25/2002 | CA2431919A1 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 07/25/2002 | CA2431506A1 Benz(g) indoles and their use as spla2 inhibitors |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | CA2425125A1 Method of treating parkinson's disease |
| 07/25/2002 | CA2406342A1 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby |
| 07/25/2002 | CA2369212A1 Combination therapy |
| 07/24/2002 | EP1225225A2 Osteogenic devices |
| 07/24/2002 | EP1225223A1 p21Cip1 REMEDIES FOR RHEUMATISM |
| 07/24/2002 | EP1225184A1 Human antithrombin variants |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1225173A1 Naphthyridine derivatives |
| 07/24/2002 | EP1224945A1 Tension-relieving agents for ciliary muscle |
| 07/24/2002 | EP1224941A2 Antithrombin III used in diseases caused by angiogenesis |
| 07/24/2002 | EP1224936A1 Physical strength enhancing agents and glycogen accumulation promoting agents |
| 07/24/2002 | EP1224933A1 New combination of active ingredients containing alfuzosine and apomorphine |
| 07/24/2002 | EP1224932A1 Drugs inhibiting cell death |
| 07/24/2002 | EP1224930A1 Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression |
| 07/24/2002 | EP1224861A1 Animal with the mass expression of human gene and test method by using the animal |
| 07/24/2002 | EP1224474A1 Multiwell scanner and scanning method |
| 07/24/2002 | EP1224313A1 Adeno-associated viruses and uses thereof |